ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Polystyrene nanoplastics exacerbate gentamicin-induced nephrotoxicity in adult rat by activating oxidative stress, inflammation and apoptosis pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular and Cellular Effects of Microplastics and Nanoplastics in the Pathogenesis of Cardiovascular, Nervous, Urinary, Digestive, and Reproductive System Diseases: A Global Systematic Review.International journal of molecular sciences · 2025Pooled it
- Emerging evidence on micro- and nanoplastics carcinogenicity: mechanisms, models, and signaling networks.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoplastics (NPs) and pharmaceutical residues are environmental pollutants that can bioaccumulate in the food chain, thus increasing the risk of harmful effects due to concomitant exposure in both humans and animals. However, the impact of such co-exposure on target tissue toxicity and mechanism remains unclear. In this study, we aimed to investigate the effect of combined exposure to widespread polystyrene NP (Ps-NP) contaminant and a widely used antibiotic, gentamicin (GEN) on nephrotoxicity in adult rat. A total of 40 male Wistar rats were assigned into four groups; control group (C), GEN exposed-group (100 mg/kg/day, i.p.), Ps-NPs exposed-group (2.5 mg/kg/day, orally) and co-exposure-group (100 mg Ps-NPs/kg/day orally + 2.6 mg GEN/kg/day i.p.) for 15 consecutive days. Kidneys were excised at sacrifice on day 15 for the examination of: (i) renal function parameters and renal oxidative stress (oxidant and antioxidant markers); (ii) mRNA expression of key regulators of oxidative stress and inflammation response (NF-κB, TNF-α, IL-6 and NRF-2) and mitochondrial apoptosis pathway (Bax, Bcl-2, caspase-9 and caspase-3); (iii) histopathology. Levels of urea and creatinine in serum of NPs or/and GEN-treated rats were significantly increased with marked histopathological changes in the kidney. Additionally, the oxidative stress markers (MDA, PCO and NO) were increased with a decrease of antioxidant enzyme activities. Furthermore, Ps-NPs or/and GEN-treated rats exhibited increased expression of mRNA related to oxidative stress (NRF-2), inflammation (TNF-α, IL-6) and apoptosis (Bax, Bcl-2, caspase-9 and caspase-3). Our results revealed that co-exposure of adult rats to Ps-NPs and GEN had a synergic-adverse effect on the kidney function. This study highlights a new finding regarding the combined toxicity of NPs and pharmaceutical pollutants on kidney function, suggesting potential synergistic interaction between these substances.
Indexed as
Identifiers
39960559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.